HUTCHMED (LON:HCM) Sets New 52-Week Low – Here’s What Happened

HUTCHMED (China) Limited (LON:HCM)’s stock price hit a new 52-week low on Tuesday . The company traded as low as GBX 182 and last traded at GBX 182, with a volume of 13008 shares traded. The stock had previously closed at GBX 191.30.

HUTCHMED Price Performance

The company has a quick ratio of 2.97, a current ratio of 4.96 and a debt-to-equity ratio of 7.91. The business has a 50-day moving average price of GBX 208.06 and a two-hundred day moving average price of GBX 213.46. The company has a market capitalization of £1.56 billion, a price-to-earnings ratio of 3.42 and a beta of 0.45.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).